|Countries||Cross sectional (N, age)||Prospective (N)||CVD Incidence (N)||Ethnicity, Gender|
|a) Australia||250 (20-30 yrs)||-||-||Bi-ethnic, bi-gender|
|b) Germany||80 (25-45 yrs)||-||-||Europid, bi-gender|
|c) Luxembourg||1432 (18-69 yrs)||1000||1432||Europid, bi-gender|
|d) South Africa||1609 ( 20-65 yrs)||359||409||Bi-ethnic, bi-gender|
|e) Sweden||3500 (20-60 yrs)||-||3500||Europid, bi-gender|
|g) Switzerland||146 (18-65 yrs)||107 (3-month
N=count; yrs=years; CVD=cardiovascular diseases.
Data sources for the meta-analysis will include the participating cohorts in the application phase of the StresSed tool:
a) Australia (Melbourne): The Alfred is a case-control cross-sectional study, including 250 individuals (20-30 years) with/without the metabolic syndrome. Participants did not receive any pharmacological treatment.
b) Germany (Dresden): The Broken Heart Syndrome (Takotsubo) study is a case-control cross-sectional study, is completed and includes 80 individuals (25-45 years).
c) Luxembourg: Observation of Cardiovascular Risk in Luxembourg (ORISCAV.Lux) is a prospective study (2007-2017) and includes 1432 individuals (18-69 years).
d) South Africa (Potchefstroom): The Hypertension in Africa Research Team (2008-2017) provides a cross sectional cohort including 1609 individuals (20-65 years).
e) South Africa (Johannesburg): The South African Breast Cancer (SABC) is a case-control cross sectional population-based study (2014-2017) and includes 500 controls (20-65 years).
g) Sweden (Mälmo): The Malmö Offspring Study (MOS) is a prospective study of first and second generation offspring of participants from the Malmö Diet and Cancer Study (MDC). Completed (2017) and includes 3500 individuals (20-60 years).
h) Switzerland (Bern): The Myocardial Infarction – Stress Prevention Intervention, MI-SPRINTrandomized controlled psychological prospective trial; is completed (2016) and includes 190 individuals (18-65 years).